Bob Hugin, who spent $36 million of his own money last year to win 43% of the vote in a race for United States Senator, has joined the board of Allergan, a pharmaceutical company.
Allergen is Parsippany-based specialty drug maker that moved to Ireland in 2013 to avoid paying U.S. taxes on their revenues.
“In Allergan, I see a company with market leading positions in four therapeutic areas, a promising R&D pipeline and a focus on executing its business strategy,” Hugin said in a statement released by the company. “I look forward to contributing to the board’s effective, independent oversight of Allergan’s strategy.”
Hugin faced considerable criticism for the cost of life-saving cancer drugs manufactured by New Jersey-based Celgene, where he served as CEO and executive chairman.
“These guys are made for each other,” said Patients for Affordable Drugs president David Mitchell in a tweet. “Both abusers of patients and the law. Both blocked generic competition to extend old product monopoly. Both their companies weaker as result.”
Mitchell’s group spent nearly $3.3 million on TV ads bashing Hugin.
The news of Hugin’s appointment was first reported by Endpoints News, which speculated that Hugin could be in line to serve as the next chairman.